Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 3/20 | 0.33 |
| ▸ | JAK3 | P52333 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | TNF | P01375 | 9/20 | 0.33 |
| ▸ | LITAF | Q99732 | 9/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13398127 | 1.00 | JAK1 (0.33) | JAK1JAK3JAK2TNFLITAF | |
| SCHEMBL13398140 | 0.88 | TNF (0.32) | JAK1JAK3JAK2TNFLITAF | |
| SCHEMBL14697426 | 0.82 | JAK2 (0.34) | JAK1JAK3JAK2TNFLITAF | |
| SCHEMBL14697153 | 0.81 | KDM4E (0.35) | JAK1JAK3JAK2BRD4CREBBP | |
| SCHEMBL3314301 | 0.81 | BRD4 (0.34) | BRD4CREBBP | |
| SCHEMBL14697235 | 0.80 | JAK1 (0.38) | JAK1JAK3JAK2TNFLITAF | |
| SCHEMBL20944715 | 0.79 | JAK2 (0.55) | JAK1JAK3JAK2TNFLITAF | |
| SCHEMBL20944562 | 0.79 | JAK2 (0.55) | JAK1JAK3JAK2TNFLITAF | |
| SCHEMBL20944680 | 0.79 | JAK2 (0.55) | JAK1JAK3JAK2TNFLITAF | |
| SCHEMBL2315569 | 0.79 | JAK2 (0.49) | JAK1JAK3JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105661-A1 | CONDENSED PYRIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100105661-A1 | CONDENSED PYRIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-29 | — | — | US | disclosed |
| EP-2123651-A1 | CONDENSED PYRIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105661-A1 | CONDENSED PYRIDINE COMPOUND | JAK3, IRAK3, JAK1 | JAK1 3/4885JAK3 1/4885JAK2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.